期刊
CURRENT ONCOLOGY REPORTS
卷 13, 期 1, 页码 42-49出版社
SPRINGER
DOI: 10.1007/s11912-010-0144-x
关键词
Biomarkers; Glioma; Neurooncology trials; Biomarker enrichment design; Marker by treatment interaction design; Adaptive design
类别
资金
- Merck
- Millenium
- Basilea
- Bristol-Meyers Squibb
- Array Biopharma
- Lilly
- Novartis
- Schering
- Merck KGaA
- [CA-108961]
Advances in molecular genetics have aided the identification of potential biomarkers with significant clinical promise in neurooncology. These advances and the evolution of targeted therapeutics necessitate the development and incorporation of innovative clinical trial designs that can effectively validate and assess the clinical utility of biomarkers. In this article, we review the use and potential of several such designs in neurooncology trials in order to support the development of personalized treatment approaches for brain tumor patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据